
|Videos|December 24, 2019
Progression on Frontline Ibrutinib in CLL
Advertisement
Transcript:
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Relacorilant Plus Nab-Paclitaxel Meets OS End Point of ROSELLA Trial in PROC
2
Unpacking the FDA Approvals That Reshaped Cancer Care in 2025
3
ILUSTRO Trial Signals Role for First-Line Zolbetuximab-Based Triplet for Biomarker-Selected Gastric Cancer
4
GDF-15 Blockade May Deepen Neoadjuvant IO Response in Cisplatin-Ineligible MIBC
5
























































































